198 related articles for article (PubMed ID: 25202043)
1. Neoadjuvant strategy as initial treatment in resectable pancreatic cancer: concrete evidence of benefit.
DE Felice F; Musio D; Raffetto N; Tombolini V
Anticancer Res; 2014 Sep; 34(9):4673-6. PubMed ID: 25202043
[TBL] [Abstract][Full Text] [Related]
2. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
[TBL] [Abstract][Full Text] [Related]
3. [Carcinoma of the pancreas: current status of multimodal therapy].
Keck T
Zentralbl Chir; 2011 Aug; 136(4):352-8. PubMed ID: 21773958
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant/downstaging radiochemotherapy in marginally resectable pancreatic cancer.
Ansari D; Kervinen M; Andersson R
Hepatogastroenterology; 2014; 61(136):2387-90. PubMed ID: 25699388
[TBL] [Abstract][Full Text] [Related]
5. [Surgery for pancreatic cancer].
Welsch T; Büchler MW; Schmidt J
Z Gastroenterol; 2008 Dec; 46(12):1393-403. PubMed ID: 19053009
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
[TBL] [Abstract][Full Text] [Related]
7. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
[TBL] [Abstract][Full Text] [Related]
8. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
[TBL] [Abstract][Full Text] [Related]
9. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy.
Maeda S; Moore AM; Yohanathan L; Hata T; Truty MJ; Smoot RL; Cleary SP; Nagorney DM; Grotz TE; Park EJ; Girgis MD; Reber HA; Motoi F; Masuda T; Unno M; Kendrick ML; Donahue TR
Surgery; 2020 May; 167(5):803-811. PubMed ID: 31992444
[TBL] [Abstract][Full Text] [Related]
10. A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer.
Goff SL; Chabot JA
Cancer J; 2012; 18(6):602-8. PubMed ID: 23187848
[TBL] [Abstract][Full Text] [Related]
11. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
di Sebastiano P; Grottola T; di Mola FF
Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
[TBL] [Abstract][Full Text] [Related]
12. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
[TBL] [Abstract][Full Text] [Related]
13. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
14. [Surgical therapy of locally advanced and primary inoperable pancreatic carcinoma after neoadjuvant preoperative radiochemotherapy].
Rau HG; Wichmann MW; Wilkowski R; Heinemann V; Sackmann M; Helmberger T; Dühmke E; Schildberg FW
Chirurg; 2002 Feb; 73(2):132-7. PubMed ID: 11974476
[TBL] [Abstract][Full Text] [Related]
15. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.
Brown KM; Siripurapu V; Davidson M; Cohen SJ; Konski A; Watson JC; Li T; Ciocca V; Cooper H; Hoffman JP
Am J Surg; 2008 Mar; 195(3):318-21. PubMed ID: 18308038
[TBL] [Abstract][Full Text] [Related]
16. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
[TBL] [Abstract][Full Text] [Related]
17. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma.
Stojadinovic A; Brooks A; Hoos A; Jaques DP; Conlon KC; Brennan MF
J Am Coll Surg; 2003 Jun; 196(6):954-64. PubMed ID: 12788434
[TBL] [Abstract][Full Text] [Related]
18. [Neoadjuvant and adjuvant therapy of ductal pancreatic carcinoma].
Hohenberger W; Kastl S
Zentralbl Chir; 2000; 125(4):348-55. PubMed ID: 10829315
[TBL] [Abstract][Full Text] [Related]
19. Management of borderline resectable pancreatic adenocarcinoma.
Jia Y; Wang TJ; Allendorf J; Saif MW
JOP; 2012 Mar; 13(2):147-50. PubMed ID: 22406587
[TBL] [Abstract][Full Text] [Related]
20. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer.
Miura JT; Krepline AN; George B; Ritch PS; Erickson BA; Johnston FM; Oshima K; Christians KK; Evans DB; Tsai S
Surgery; 2015 Dec; 158(6):1545-55. PubMed ID: 26243342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
